- PTC Therapeutics press release ( NASDAQ: PTCT ): Q4 GAAP EPS of -$2.35 misses by $0.78 .
- Revenue of $167.41M (+1.3% Y/Y) misses by $15.66M .
-
PTC Reaffirms Full Year 2023 Financial Guidance:
- PTC anticipates total revenues for the full year 2023 to be between $940 million and $1.0 billion vs. $915.95M consensus
- PTC anticipates net product revenues for the DMD franchise for the full year 2023 to be between $545 million and $565 million.
- PTC anticipates GAAP R&D and SG&A expense for the full year 2023 to be between $1.01 billion and $1.06 billion.
For further details see:
PTC Therapeutics GAAP EPS of -$2.35 misses by $0.78, revenue of $167.41M misses by $15.66M